SCHEMBL26326972

SCHEMBL26326972

COC(c1ccc(C(=O)OCc2ccccc2)cc1)c1ccc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 7/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
MLKL Q8NB16 1/20 0.48
RAB9A P51151 4/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
RARA P10276 1/20 0.46
RARB P10826 1/20 0.46
RARG P13631 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
ADRB2 P07550 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706461 0.80 KMT2A (0.66) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL1898197 0.79 LMNA (0.50) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL15614364 0.79 KMT2A (0.69) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL23795853 0.78 KMT2A (0.63) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL6002245 0.77 KMT2A (0.70) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL28152491 0.77 MAPT (0.69) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL27366043 0.75 AKR1C3 (0.49) TDP1ALDH1A1L3MBTL1
SCHEMBL312287 0.75 KMT2A (0.92) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL9329147 0.74 KMT2A (0.67) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL2704247 0.74 KMT2A (0.71) KMT2ATDP1SLC6A2SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE HPD, TALDO1, OGG1 KMT2A 1249/4885TDP1 2696/4885SLC6A2 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.